The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Solitary Pulmonary Nodule

Discrete, well-defined opacity ≤30 mm in lung surrounded by aerated parenchyma — workup balances cancer risk with benign causes using risk models, imaging features, and stepwise surveillance.

Written by: Saygı Hospital Health Guide Editorial Board
Published:

This content is for general information; please consult your physician for diagnosis and treatment.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göğüs Hastalıkları department. Book Appointment →

What is Solitary Pulmonary Nodule?

A solitary pulmonary nodule is a focal opacity ≤30 mm completely surrounded by lung parenchyma. Larger lesions are termed lung masses. SPNs are commonly detected incidentally on imaging or in lung cancer screening programs.

Etiology spectrum: malignant (40–60% in symptomatic adults, lower in screening populations) — primary adenocarcinoma, squamous cell, large cell, small cell carcinoma, carcinoid, solitary metastasis; benign — infectious granulomas (TB, histoplasmosis, coccidioidomycosis), hamartoma, intrapulmonary lymph node, AVM, infarct, organizing pneumonia.

Risk stratification combines clinical (age, smoking pack-years, prior cancer, exposure history) and imaging features (size, edge characteristics, density, growth rate, contrast enhancement, FDG-PET avidity). Brock model, Mayo Clinic model, and VA model estimate malignancy probability.

Symptoms

Asymptomatic — most SPNs detected incidentally on chest CT or chest X-ray
Cough, hemoptysis (rare with peripheral SPN, more concerning if present)
Constitutional symptoms: weight loss, fatigue (raise malignancy concern)
Chest pain (rare unless pleural involvement)
Shortness of breath (suggests larger or central tumor)
Symptoms of metastatic disease (bone pain, headache, neurologic deficits)

Risk Factors

Age >50 years
Smoking history (pack-years correlate with risk)
Family history of lung cancer
Personal history of cancer (especially with metastatic potential)
Occupational exposure: asbestos, silica, radon, diesel exhaust
Chronic lung disease: COPD, pulmonary fibrosis
Immunocompromise (infectious causes)
Geographic exposure: TB-endemic areas, fungal-endemic regions

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Newly detected pulmonary nodule on chest imaging — pulmonologist or thoracic specialist referral
  • Hemoptysis with known nodule
  • Growth or change in nodule on serial imaging
  • New constitutional symptoms (weight loss, fever)
  • Spiculated, irregular, or part-solid nodule on CT
  • PET-positive lesion or FDG uptake on screening

Treatment Methods

01
Initial evaluation: comparison with prior imaging (stability >2 years for solid nodule generally benign), high-resolution thin-slice CT chest with thin-section reconstruction, characterization (size, density, edge, calcification pattern)
02
Fleischner Society guidelines (2017) for incidental nodules: solid <6 mm low-risk — no follow-up; solid 6–8 mm — CT at 6–12 months; solid >8 mm — CT at 3 months, PET-CT, or biopsy; subsolid (ground-glass) — CT at 6–12 months then 2-yearly to 5 years; part-solid — sustained follow-up due to adenocarcinoma risk
03
Lung-RADS for screening: low-dose CT in NLST/USPSTF criteria patients (age 50–80, ≥20 pack-years, smoking within 15 years), categorized 1–4X with management algorithm
04
PET-CT for nodules >8 mm solid: high SUV uptake (>2.5) suggests malignancy, but inflammatory and infectious causes can be PET-positive
05
Tissue sampling: CT-guided transthoracic needle biopsy (peripheral lesions, pneumothorax risk 15–25%), bronchoscopy with EBUS-TBNA (central or peri-bronchial), navigational bronchoscopy with electromagnetic guidance, video-assisted thoracoscopic surgery (VATS) wedge resection for indeterminate cases or definitive treatment
06
Molecular testing on biopsy: EGFR, ALK, ROS1, KRAS, BRAF, MET, RET, NTRK, PD-L1 for targeted and immunotherapy options
07
Surgical resection (definitive treatment for resectable lung cancer): VATS or robotic lobectomy, segmentectomy or wedge resection for peripheral early-stage disease, mediastinal lymph node sampling/dissection
08
Stereotactic body radiotherapy (SBRT) for medically inoperable early-stage NSCLC: 4–8 fractions, comparable local control to surgery in select patients
09
Treatment of benign causes: antifungal therapy for fungal granuloma, antibiotics for infectious cause, observation for hamartoma or AVM
10
Multidisciplinary discussion in tumor board for indeterminate or borderline lesions
11
Survivorship: surveillance imaging post-resection per stage (every 3–6 months years 1–3, then yearly), smoking cessation, pulmonary rehabilitation

Which Department to Visit?

You can visit our Göğüs Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Göğüs Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Asthma

Göğüs Hastalıkları

Asthma is characterized by wheezing, coughing and shortness of breath attacks; with proper treatment it can be kept under control.

COPD (Chronic Obstructive Pulmonary Disease)

Göğüs Hastalıkları

COPD is an irreversible lung disease characterized by shortness of breath and chronic cough; quitting smoking slows its progression.

Pneumonia

Göğüs Hastalıkları

Pneumonia presents with high fever, cough and shortness of breath; the vast majority recover with appropriate antibiotic treatment.

Tuberculosis (TB)

Göğüs Hastalıkları

Tuberculosis presents with weeks-to-months of cough, fever, and night sweats; early diagnosis and treatment lead to full recovery.

Pleural Effusion

Göğüs Hastalıkları

Pleural effusion is the accumulation of excess fluid in the pleural space, resulting from imbalances in fluid production and removal, and represents a manifestation of diverse cardiopulmonary, infectious, and malignant disorders.

Pneumothorax

Göğüs Hastalıkları

Pneumothorax is the presence of air in the pleural space resulting in partial or complete lung collapse, classified as spontaneous (primary/secondary), traumatic, or iatrogenic, with tension pneumothorax representing a life-threatening emergency.

Bronchitis (Acute and Chronic)

Göğüs Hastalıkları

Acute bronchitis is mostly viral and resolves spontaneously, while chronic bronchitis is a smoking-related component of COPD.

Bronchiectasis

Göğüs Hastalıkları

Bronchiectasis is a chronic respiratory disease characterized by permanent, abnormal dilation of bronchi with associated destruction of muscular and elastic components of airway walls, resulting in impaired mucociliary clearance and recurrent infection.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.